Literature DB >> 2619337

In vitro chemosensitivity testing in the treatment of ovarian carcinoma.

H Auner1, E Petru, H M Hofmann, H Pickel, P Pürstner.   

Abstract

In vitro chemosensitivity to cisplatinum, adriamycin, cyclophosphamide, and 5-fluorouracil was investigated in 58 cases of ovarian carcinoma using Volm's short-term test. These in vitro results were retrospectively correlated with the relapse-free interval. Operative treatment in all patients (FIGO stage I (5), III (43), IV (10)) comprised maximum debulking procedure including hysterectomy, adnexectomy, omentectomy, pelvic and in most cases additionally paraaortic lymphadenectomy. Subsequently, all patients were treated with the cisplatinum-epirubicin-cyclophosphamide regimen. 33/58 tumors (66%) were sensitive in vitro (inhibition of nucleic acid precursor incorporation of more than 45% as compared to untreated controls). The median relapse-free interval of patients with sensitive tumors was significantly longer than that of those with resistant carcinomas (30.3 versus 22.6 months, respectively; P less than 0.05). Histopathological evaluation showed the majority of serous cystadenocarcinomas to be sensitive (26/33 = 79%, P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2619337     DOI: 10.1007/bf00934523

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  15 in total

Review 1.  Review: biologic heterogeneity of cancer metastases.

Authors:  I J Fidler
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

2.  Comparison of in vivo and in vitro activity of estrogen-linked nitrosoureas in methylnitrosourea-induced rat mammary carcinoma.

Authors:  E Petru; M R Berger; M Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 3.  Clinical relevance of predictive tests for cancer chemotherapy.

Authors:  J Mattern; M Volm
Journal:  Cancer Treat Rev       Date:  1982-12       Impact factor: 12.111

4.  Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy.

Authors:  M Volm; K Wayss; M Kaufmann; J Mattern
Journal:  Eur J Cancer       Date:  1979-07       Impact factor: 9.162

5.  [In-vitro testing of the sensitivity of mammary carcinoma cells to cytostatic drugs (author's transl)].

Authors:  G Bastert; H Schmidt-Matthiesen; R Gerner; R T Michel; D Nord; G Leppien
Journal:  Dtsch Med Wochenschr       Date:  1975-10-03       Impact factor: 0.628

6.  [Possibilities and limits of pre-therapeutic neoplasm sensitivity cytostatics tests under short-term conditions].

Authors:  M Volm; M Kaufmann; J Mattern; K Wayss
Journal:  Schweiz Med Wochenschr       Date:  1975-01-18

Review 7.  [On the problem of praetherapeutic sensitivity testing of human tumours based on incorporation studies of nucleic acid precursors in vitro (author's transl)].

Authors:  S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1977-12-01

8.  [Results of testing tumor resistance (in vitro--in vivo) in breast cancer].

Authors:  G Bartzke; H Rössler; R Seufert; V Möbus; R Kreienberg
Journal:  Geburtshilfe Frauenheilkd       Date:  1987-10       Impact factor: 2.915

9.  Use of in vitro method to predict response of human ovarian carcinoma cells to chemotherapeutic agents.

Authors:  K Buckshee; P K Roy; T N Chapekar
Journal:  Int J Gynaecol Obstet       Date:  1984-10       Impact factor: 3.561

10.  [In vitro resistance testing of tumors in relation to cytostatics. 2. Examinations with human malignomas].

Authors:  K Possinger; R Hartenstein; H Ehrhart
Journal:  Onkologie       Date:  1980-12
View more
  2 in total

1.  Relationship between chemoresistance of lung tumours and cigarette smoking.

Authors:  M Volm; B Samsel; J Mattern
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

2.  Protein expression profiles indicative for drug resistance of non-small cell lung cancer.

Authors:  M Volm; R Koomägi; J Mattern; T Efferth
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.